[Comment] Brentuximab vedotin for advanced Hodgkin's lymphoma

Brentuximab vedotin —through CD30-targeted delivery of monomethyl auristatin E into Hodgkin Reed-Sternberg cells—has transformed the management of patients with classical Hodgkin's lymphoma, through both its high frequency and long duration of complete remission.1 Since the initial approval of this agent, there has been high interest in its successful integration into earlier lines of management.2–4
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research